Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.
BRCA1/BRCA2
cancer susceptibility genes
genetic screening
predominant Israeli pathogenic variants
unselected population
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
revised:
08
03
2021
received:
03
02
2021
accepted:
12
03
2021
pubmed:
23
6
2021
medline:
11
3
2022
entrez:
22
6
2021
Statut:
ppublish
Résumé
Several recurring pathogenic variants in BRCA1/BRCA2 and other cancer susceptibility genes are encountered in ethnically diverse Jewish populations. The yield of genotyping for these recurring pathogenic variants in healthy Israeli individuals unselected for ethnicity, sex, or a family history of cancer has not been previously reported. Individuals voluntarily participating in annual medical surveillance at the Institute of Medical Screening of Sheba Medical Center were offered genotyping for predominant pathogenic variants in BRCA1/BRCA2 and recurring variants in CHEK2, MUTYH, APC, and the Lynch syndrome genes via a chip-based assay at the oncogenetic service of Sheba Medical Center from May 15, 2018, to December 15, 2020. All study participants were unrelated to one another. The study was approved by the Sheba ethics committee. Overall, 1764 individuals, including 1008 females (57%), with a mean age of 54.2 years (range, 25-86 years) were genotyped. The yield of the testing was 4% (71 of 1764), and it was higher in Ashkenazi Jews (AJs) and mixed AJ-non-AJ participants (4.75% [58 of 1222]; 1.8% for BRCA1/BRCA2 pathogenic variants) than non-AJ patients (2.2% [9 of 401]; 1% for BRCA1 pathogenic variants). When BRCA1/BRCA2 pathogenic variants were excluded, 2.44% carried low-penetrance variants, including CHEK2 c.1283C>T (n = 3), APC c.3920T>A (n = 36), and heterozygous MUTYH c.1187G>A (n = 4). A family history of cancer was not associated with a higher yield of pathogenic variant detection. The observed rates of positive genotyping in a healthy, unselected, multiethnic Israeli population warrant consideration of the inclusion of targeted genotyping of selected pathogenic variants in high-penetrance and perhaps lower penetrance cancer susceptibility genes for all Jewish individuals in Israel, regardless of their ethnicity or family history of cancer.
Sections du résumé
BACKGROUND
Several recurring pathogenic variants in BRCA1/BRCA2 and other cancer susceptibility genes are encountered in ethnically diverse Jewish populations. The yield of genotyping for these recurring pathogenic variants in healthy Israeli individuals unselected for ethnicity, sex, or a family history of cancer has not been previously reported.
METHODS
Individuals voluntarily participating in annual medical surveillance at the Institute of Medical Screening of Sheba Medical Center were offered genotyping for predominant pathogenic variants in BRCA1/BRCA2 and recurring variants in CHEK2, MUTYH, APC, and the Lynch syndrome genes via a chip-based assay at the oncogenetic service of Sheba Medical Center from May 15, 2018, to December 15, 2020. All study participants were unrelated to one another. The study was approved by the Sheba ethics committee.
RESULTS
Overall, 1764 individuals, including 1008 females (57%), with a mean age of 54.2 years (range, 25-86 years) were genotyped. The yield of the testing was 4% (71 of 1764), and it was higher in Ashkenazi Jews (AJs) and mixed AJ-non-AJ participants (4.75% [58 of 1222]; 1.8% for BRCA1/BRCA2 pathogenic variants) than non-AJ patients (2.2% [9 of 401]; 1% for BRCA1 pathogenic variants). When BRCA1/BRCA2 pathogenic variants were excluded, 2.44% carried low-penetrance variants, including CHEK2 c.1283C>T (n = 3), APC c.3920T>A (n = 36), and heterozygous MUTYH c.1187G>A (n = 4). A family history of cancer was not associated with a higher yield of pathogenic variant detection.
CONCLUSIONS
The observed rates of positive genotyping in a healthy, unselected, multiethnic Israeli population warrant consideration of the inclusion of targeted genotyping of selected pathogenic variants in high-penetrance and perhaps lower penetrance cancer susceptibility genes for all Jewish individuals in Israel, regardless of their ethnicity or family history of cancer.
Substances chimiques
BRCA1 Protein
0
BRCA2 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3599-3604Informations de copyright
© 2021 American Cancer Society.
Références
Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer predisposing BRCA1/BRCA2 pathogenic variants in the Ashkenazi-Jewish Community: a randomized controlled trial. J Natl Cancer Inst. 2015;107:dju379. doi:10.1093/jnci/dju379
Metcalfe KA, Poll A, Royer R, et al. Screening for founder pathogenic variants in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2009;28:387-391. doi:10.1200/JCO.2009.25.0712
Lieberman S, Tomer A, Ben-Chetrit A, et al. Population screening for BRCA1/BRCA2 founder pathogenic variants in Ashkenazi Jews: proactive recruitment compared with self-referral. Genet Med. 2017;19:754-762. doi:10.1038/gim.2016.182
Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 pathogenic variant testing in unselected general population women. J Natl Cancer Inst. 2018;110:714-725. doi:10.1093/jnci/djx265
Dorling L, Carvalho S, Allen J, et al; Breast Cancer Association Consortium. Breast cancer risk genes-association analysis in more than 113,000 women. N Engl J Med. 2021;384:428-439. doi:10.1056/NEJMoa1913948
Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. Published online January 20, 2021. doi:10.1056/NEJMoa2005936
Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to pathogenic variants in BRCA1 and BRCA2. Genet Med. 2010;12:245-259. doi:10.1097/GIM.0b013e3181d38f2f
Foulkes WD, Knoppers BM, Turnbull C. Population genetic testing for cancer susceptibility: founder pathogenic variants to genomes. Nat Rev Clin Oncol. 2016;13:41-54. doi:10.1038/nrclinonc.2015.173
Bernstein-Molho R, Laitman Y, Schayek H, et al. The yield of targeted genotyping for the recurring pathogenic variants in BRCA1/2 in Israel. Breast Cancer Res Treat. 2018;167:697-702. doi:10.1007/s10549-017-4551-7
Bernstein-Molho R, Singer A, Laitman Y, Netzer I, Zalmanoviz S, Friedman E. Multigene panel testing in unselected Israeli breast cancer cases: pathogenic variantal spectrum and use of BRCA1/2 pathogenic variant prediction algorithms. Breast Cancer Res Treat. 2019;176:165-170. doi:10.1007/s10549-019-05228-6
Liang J, Lin C, Hu F, et al. APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis. Am J Epidemiol. 2013;177:1169-1179. doi:10.1093/aje/kws382
Shaag A, Walsh T, Renbaum P, et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet. 2005;14:555-563. doi:10.1093/hmg/ddi052
Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26:542-548. doi:10.1200/JCO.2007.12.5922
Raskin L, Schwenter F, Freytsis M, et al. Characterization of two Ashkenazi Jewish founder pathogenic variants in MSH6 gene causing Lynch syndrome. Clin Genet. 2011;79:512-522. doi:10.1111/j.1399-0004.2010.01594.x
Mukherjee B, Rennert G, Ahn J, et al. High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder pathogenic variant. Gastroenterology. 2011;140:1919-1926. doi:10.1053/j.gastro.2011.02.071
Goldberg Y, Barnes-Kedar I, Lerer I, et al. Genetic features of Lynch syndrome in the Israeli population. Clin Genet. 2015;87:549-553. doi:10.1111/cge.12530
Lejbkowicz F, Cohen I, Barnett-Griness O, et al. Common MUTYH pathogenic variants and colorectal cancer risk in multiethnic populations. Fam Cancer. 2012;11:329-335. doi:10.1007/s10689-012-9516-8
Shaye K, Amir T, Shlomo S, Yechezkel S. Fasting glucose levels within the high normal range predict cardiovascular outcome. Am Heart J. 2012;164:111-116. doi:10.1016/j.ahj.2012.03.023
Schayek H, De Marco L, Starinsky-Elbaz S, et al. The rate of recurrent BRCA1, BRCA2, and TP53 pathogenic variants in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. Cancer Genet. 2016;209:50-52. doi:10.1016/j.cancergen.2015.11.003
Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common pathogenic variants in BRCA1 and BRCA2. Nat Genet. 1996;14:185-187. doi:10.1038/ng1096-185
Patel S, Legood R, Evans DG, et al. Cost effectiveness of population based BRCA1 founder pathogenic variant testing in Sephardi Jewish women. Am J Obstet Gynecol. 2018;218:431.e1-431.e12. doi:10.1016/j.ajog.2017.12.221
Manchanda R, Patel S, Antoniou AC, et al. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. Am J Obstet Gynecol. 2017;217:578.e1-578.e12. doi:10.1016/j.ajog.2017.06.038
Michaan N, Leshno M, Safra T, Sonnenblick A, Laskov I, Grisaru D. Cost effectiveness of whole population BRCA genetic screening for cancer prevention in Israel. Cancer Prev Res (Phila). Published online December 22, 2020. doi:10.1158/1940-6207.CAPR-20-0411
Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2018;37:453-460. doi:10.1200/JCO.18.01631
Møller P, Hagen AI, Apold J, et al. Genetic epidemiology of BRCA pathogenic variants-family history detects less than 50% of the pathogenic variant carriers. Eur J Cancer. 2007;43:1713-1717. doi:10.1016/j.ejca.2007.04.023
Locker GY, Lynch HT. Genetic factors and colorectal cancer in Ashkenazi Jews. Fam Cancer. 2004;3:215-221. doi:10.1007/s10689-004-9547-x
Bernstein-Molho R, Friedman E, Kedar I, et al. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants. Breast Cancer Res Treat. 2020;181:445-453. doi:10.1007/s10549-020-05633-2
Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility pathogenic variants. Nat Rev Clin Oncol. 2016;13:581-588. doi:10.1038/nrclinonc.2016.90
Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17:70-87. doi:10.1038/gim.2014.147